WO2003097098A1 - Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic - Google Patents

Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic Download PDF

Info

Publication number
WO2003097098A1
WO2003097098A1 PCT/EP2003/005188 EP0305188W WO03097098A1 WO 2003097098 A1 WO2003097098 A1 WO 2003097098A1 EP 0305188 W EP0305188 W EP 0305188W WO 03097098 A1 WO03097098 A1 WO 03097098A1
Authority
WO
WIPO (PCT)
Prior art keywords
renal
diabetic
disease
hypertension
heart failure
Prior art date
Application number
PCT/EP2003/005188
Other languages
French (fr)
Inventor
David Louis Feldman
Randy Lee Webb
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03730064A priority Critical patent/EP1507558B8/en
Priority to JP2004505094A priority patent/JP5288678B2/en
Priority to KR1020137023159A priority patent/KR20130109244A/en
Priority to CA2485081A priority patent/CA2485081C/en
Priority to KR10-2004-7018479A priority patent/KR20050008717A/en
Priority to AU2003240669A priority patent/AU2003240669B2/en
Priority to US10/514,683 priority patent/US20050182042A1/en
Priority to BR0310084-7A priority patent/BR0310084A/en
Priority to MXPA04011383A priority patent/MXPA04011383A/en
Priority to DK03730064.7T priority patent/DK1507558T3/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to AT03730064T priority patent/ATE520417T1/en
Priority to NZ536555A priority patent/NZ536555A/en
Priority to SI200332071T priority patent/SI1507558T1/en
Publication of WO2003097098A1 publication Critical patent/WO2003097098A1/en
Priority to IL164837A priority patent/IL164837A/en
Priority to NO20045459A priority patent/NO334382B1/en
Priority to HK05106985.9A priority patent/HK1074774A1/en
Priority to US12/188,604 priority patent/US8183295B2/en
Priority to US13/307,567 priority patent/US20120071470A1/en
Priority to LU92000C priority patent/LU92000I2/en
Priority to CY2012011C priority patent/CY2012011I2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the renin angiotensin system is a complex hormonal system comprised of a large molecular weight precursor, angiotensinogen, two processing enzymes, renin and angiotensin converting enzyme (ACE), and the vasoactive mediator angiotensin II (Ang II) (J. Cardiovasc. Pharmacol., 15(Supp B) (1990) p. S1-S5).
  • the enzyme renin catalyzes the cleavage of angiotensinogen into the decapeptide angiotensin I, which has minimal biological activity on its own and is converted into the active octapeptide Ang II by ACE.
  • Ang II has multiple biological actions on the cardiovascular system, including vasoconstriction, activation of the sympathetic nervous system, stimulation of aldosterone production, antinatriuresis, stimulation of vascular growth (i.e., stimulation of smooth muscle cell proliferation and the deposition of excess extracellular matrix material in the vascular wall), and stimulation of cardiac growth.
  • Ang II functions as a pressor hormone and is involved in the pathophysiology of several forms of hypertension.
  • angiotensin II The vasoconstrictive effects of angiotensin II are produced by its action on the non- striated smooth muscle cells, the stimulation of the formation of the adrenergenic hormones epinephrine and norepinephrine as well as the increase of the activity of the sympathetic nervous system as a result of the formation of norepinephrine.
  • Angiotensin II also has an influence on electrolyte balance, produces e.g. antinatriuretic and antidiuretic effects in the kidney and thereby promotes the release of, on the one hand, the vasopressin peptide from the pituitary gland and, on the other hand, of aldosterone from the adrenal glomerulosa. All these influences play an important part in the regulation of blood pressure, in increasing both circulating volume and peripheral resistance.
  • Angiotensin II is also involved in cell growth and migration and in extracellular matrix formation.
  • Angiotensin II interacts with specific receptors on the surface of the target cell. It has been possible to identify receptor subtypes that are termed e.g. AT1- and AT 2-receptors. In recent times great efforts have been made to identify substances that bind to the AT1 - receptor. Such active ingredients are often termed angiotensin II antagonists. Because of the inhibition of the AT1 -receptor such antagonists can be used e.g. as antihypertensives or for the treatment of congestive heart failure, among other indications. Angiotensin II antagonists are therefore understood to be those active ingredients that bind to the AT1- receptor subtype.
  • Inhibitors of the renin angiotensin system are well known drugs that lower blood pressure and exert beneficial actions in hypertension and in congestive heart failure as described, for example, in N. Eng. J. Med. 316, 23 (1987) p. 1429-1435.
  • a large number of peptide and non-peptide inhibitors of the renin angiotensin system are known, the most widely studied being the ACE inhibitors, which include the drugs captopril, enalapril, lisinopril, benazepril and spirapril.
  • ACE inhibitors include the drugs captopril, enalapril, lisinopril, benazepril and spirapril.
  • ACE cleaves a variety of peptide substrates, including the vasoactive peptides bradykinin and substance P.
  • Prevention of the degradation of bradykinin by ACE inhibitors has been demonstrated, and the activity of the ACE inhibitors in some conditions has been reported in Circ. Res., 66, 1 (1990) p. 242-248 to be mediated by elevation of bradykinin levels rather than inhibition of Ang II formation. Consequently, it cannot be presumed that the effect of an ACE inhibitor is due solely to prevention of angiotensin formation and subsequent inhibition of the renin angiotensin system.
  • the RAS can be stopped at the beginning of its pathway.
  • This initial step i.e., the conversion of angiotensinogen to angiotensin I
  • renin inhibitors Rl
  • Renin inhibitors fully shut down the formation of angiotensin II because they act on the rate-limiting step in the cascade.
  • these agents can be demonstrated to have improved efficacy over ACE inhibitors or blockers of the AT1 receptor.
  • Rl are associated with less side effects than ACE inhibitors.
  • One such Rl is aliskiren. Others are detikiren, terlakiren, and zankiren.
  • Aliskiren has the following chemical formula (I):
  • the renin inhibitor of formula (I), chemically defined as 2(S),4(S),5(S),7(S)-N-(3-amino-2,2- dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy- propoxy)phenyl]-octanamide, is specifically disclosed in EP 678503 A. Especially preferred is the hemi-fumarate salt thereof.
  • a drawback in the treatment of hypertension and diseases and conditions related thereto is that monotherapy frequently stimulates compensatory reflexes that counteract the pharmacologically-induced reduction in blood pressure. This compensation tends to hinder successful blood pressure lowering. It is therefore desirable to develop additional means of treatment for this application.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic, or, where appropriate, in each case a pharmaceutically acceptable salt thereof, especially for the treatment of a disease or condition as set forth hereinbefore or hereinafter.
  • the invention likewise relates to the use of (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic, or, where appropriate, in each case a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease or condition as set forth hereinbefore or hereinafter.
  • a renin inhibitor e.g., a renin inhibitor, a calcium channel blocker (CCB), and (iii) a diuretic, or, where appropriate, in each case a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease or condition as set forth hereinbefore or hereinafter.
  • the invention likewise relates to a method for the treatment of a disease or conditions as set forth hereinbefore or hereinafter comprising administering to an animal, including man, a therapeutically effective amount of (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic, or, where appropriate, in each case a pharmaceutically acceptable salt thereof.
  • the present invention furthermore relates to a kit of parts comprising
  • a pharmaceutical composition of a renin inhibitor or a pharmaceutically acceptable salt thereof (i) a pharmaceutical composition of a renin inhibitor or a pharmaceutically acceptable salt thereof, (ii ) a pharmaceutical composition of a calcium channel blocker (CCB) or a pharmaceutically acceptable salt thereof, and (iii ) a pharmaceutical composition of a diuretic, or a pharmaceutically acceptable salt thereof, in the form of two or three separate units of the components (i) to (iii).
  • the renin inhibitor (i) is selected from the group consisting of aliskiren, detikiren, terlakiren, and zankiren;
  • the CCB is selected from the group consisting of amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, niguldipine, niludipine, nimodipine, nisoldipine, nitrendipine, nivaldipine, ryosidine, anipamil, diltiazem, fendiline, flunarizine, gallopamil, mibefradil, prenylamine, tiapamil and verapamil; and the diuretic (iii) is selected from the group consisting of bumetanide, ethacrynic acid, furosemide, torsemide, amiloride, spironolactone, triamter
  • the structure of the active agents identified by generic or tradenames may be taken from the actual edition of the standard compendium 'The Merck Index" or from databases, e.g. LifeCycle Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled to identify the active agents and, based on these references, likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models, both in vitro and in vivo.
  • the present invention further relates to the above pharmaceutical composition for the treatment of heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter or detrimental vascular remodeling.
  • heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter or detrimental vascular remodeling.
  • combination therapy with the inventive combination and in particular with aliskiren, especially the hemi-fumarate salt thereof, amlodipine, especially the maleate or more preferably the besylate thereof, and hydrochlorthiazide (HCTZ) proves to be beneficial in the treatment and prevention of myocardial infarction and its sequelae.
  • HCTZ hydrochlorthiazide
  • Such a combination therapy is also useful in treating atherosclerosis, angina (whether stable or unstable), and renal insufficiency (diabetic and non-diabetic). Furthermore, such a combination therapy can improve endothelial dysfunction, thereby providing benefit in diseases in which normal endothelial function is disrupted such as heart failure, angina pectoris and diabetes.
  • the combination of the present invention may be used for the treatment or prevention of secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF- ⁇ and proliferative diseases of smooth muscle cells (such as uterine fibroids).
  • renal failure conditions such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma,
  • the present invention furthermore relates to a method of treatment of a condition or a disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non- diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular
  • the invention likewise relates to the use of a combination of (i) a renin inhibitor, (ii) a CCB, and (iii) a diuretic, or pharmaceutically acceptable salts for the treatmeno of a disease or condition as described hereinbefore or hereinafter.
  • treatment embraces all the different forms or modes of treatment as known to those of the pertinent art and in particular includes preventive, curative and palliative treatment.
  • Diuretic activates the RAS, thus makes inhibition of RAS by renin inhibitor (Rl) more effective.
  • Addition of CCB to Rl, whose activity is potentiated by diuretic, will lower e.g. blood pressure by a mechanism separate from RAS.
  • CCB has been shown to be renoprotective at least in part through (i) inhibition of glomerular expression of TGF-beta & alpha-smooth muscle cell actin (Nephron 2000 Nov;86(3):315-26) and (ii) exerting growth- inhibitory activity through inhibiting multiple cell signal pathways (J Hypertens 2002 Jan;20(1):95-102).
  • the unexpected advantage of a triple vs dual combination is the (i) potentiated blod pressure lowering effect and (ii) more effective anti-proliferative effect through the combined actions of rennin inhibition (potentiated by diuretic) and CCB. Both of these activities are translated into enhanced tissue protection.
  • the improved activity and benefit over dual combo results from a potentiation or even synergistic interactions between 3 components.
  • less side effects are can be manifested by the ability to use lower doses of the partners to be combined. For example, doses of individual components can be reduced by 2-7 fold or reduced by 3-7, 4-7, 5-7 or 6-7 fold, when given in combination and still achieve comparable blood pressure lowering activity compared to each individual agent.
  • the superiority or surprising advantages of triple over dual combos can be demonstrated e.g. by testing of the combination for benefits on blood pressure lowering, left ventricular hypertrophy, renal protection (e.g., reversing, ameliorating, or delaying worsening of proteinuria; slowing decline in glomerular filtration rate or creatinine clearance, delay doubling of serum creatinine).
  • renal protection e.g., reversing, ameliorating, or delaying worsening of proteinuria; slowing decline in glomerular filtration rate or creatinine clearance, delay doubling of serum creatinine.
  • hypertensive vascular disease ultimately leads to a variety of pathological changes in target organs such as the heart and kidney.
  • the presence of diabetes exacerbates these changes.
  • Sustained hypertension can lead as well to an increased occurrence of stroke. Therefore, there is a strong need to evaluate the efficacy of antihypertensive therapy, an examination of additional cardiovascular endpoints, beyond those of blood pressure lowering, to get further insight into the benefits of combined treatment.
  • the nature of hypertensive vascular diseases is multifactorial. Under certain circumstances, drugs with different mechanisms of action have been combined. However, simply using any combination of drugs having different modes of action does not necessarily lead to combinations with advantageous effects.
  • Potentiation is the enhancement of the biological effect of one agent by another agent to produce either an additive or greater than additive biological effect, compared to the effects from the individual agents, while synergism is the enhancement of the biological effect of One agent by another agent to produce a biological effect that is greater than that predicted by adding the effects of the individual components.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising (i) aliskiren, (ii) amlodipine , and (ii) hydrochlorothiazide (HCTZ) or pharmaceutically effective salts thereof.
  • the present invention relates to methods of treating cardiac and renal related conditions by administration of the pharmaceutical composition comprising (i) aliskiren, especially the hemi-fumarate salt thereof, amlodipine, especially the maleate or more preferably the besylate thereof, and HCTZ.
  • the compounds to be combined can be present as pharmaceutically acceptable salts. If these compounds have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds having at least one acid group (for example COOH) can also form salts with bases. Corresponding internal salts may furthermore be formed, if a compound comprises e.g. both a carboxy and an amino group.
  • a combination of aliskiren, amlodipine, and HCTZ achieves greater therapeutic effect than the administration of each of these agents alone. Greater efficacy can also be documented as a prolonged duration of action.
  • the duration of action can be monitored as either the time to return to baseline prior to the next dose or as the area under the curve (AUC) and is expressed as the product of the change in blood pressure in millimeters of mercury (change in mmHg) and the duration of the effect (minutes, hours or days).
  • lower doses of the individual drugs to be combined according to the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used to diminish the incidence of side effects.
  • the combined administration of aliskiren, amlodipine, and HCTZ or pharmaceutically acceptable salts thereof results in a significant response in a greater percentage of treated patients, that is, a greater responder rate results, regardless of the underlying etiology of the condition. This is in accordance with the desires and requirements of the patients to be treated.
  • combination therapy with aliskiren, especially the hemi-fumarate salt thereof, amlodipine, especially the maleate or more preferably the besylate thereof, and HCTZ results in a more effective antihypertensive therapy (whether for malignant, essential, reno-vascular, diabetic, isolated systolic, or other secondary type of hypertension) through improved efficacy as well as a greater responder rate.
  • the combination is also useful in the treatment or prevention of heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter or detrimental vascular remodeling.
  • combination therapy with aliskiren, amlodipine, and HCTZ proves to be beneficial in the treatment and prevention of myocardial infarction and its sequelae.
  • a combination therapy with aliskiren, amlodipine, and HCTZ is also useful in treating atherosclerosis, angina (whether stable or unstable), and renal insufficiency (diabetic and non-diabetic).
  • combination therapy using aliskiren, amlodipine, and HCTZ can improve endothelial dysfunction, thereby providing benefit in diseases in which normal endothelial function is disrupted such as heart failure, angina pectoris and diabetes.
  • the combination of the present invention may be used for the treatment or prevention of secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF- ⁇ and proliferative diseases of smooth muscle cells (such as uterine fibroids).
  • renal failure conditions such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma,
  • Aliskiren is administered in subcutaneously implanted osmotic minipumps at approximately 1-200 mg/kg/day (monotherapy), and approximately 1- 75 mg kg/day (combination therapy). Amlodipine and HCTZ are administered orally in dosages below 75 mg/kg/day as mono- or combination therapy.
  • the DOCA-salt test model utilizes either an acute or chronic study protocol.
  • An acute study procedure involves assessment of the effects of various test substances over a six-hour experimental period using rats with indwelling femoral arterial and venous catheters.
  • the Acute Study Procedure evaluates test substances for their ability to reduce blood pressure during the established phase of DOCA-salt hypertension.
  • the Chronic Study Procedure assesses the ability of test substances to prevent or delay the rise in blood pressure during the development phase of DOCA-salt hypertension. Therefore, blood pressure will be monitored in the chronic study procedure by means of a radiotransmitter.
  • the radiotransmitter is surgically implanted into the abdominal aorta of rats, prior to the initiation of DOCA-salt treatment and thus, prior to the induction of hypertension. Blood pressure is chronically monitored for periods of up 6 weeks (approximately one week prior to DOCA-salt administration and for 5 weeks thereafter).
  • Rats are anesthetized with 2-3% isoflurane in oxygen inhalant followed by Amytal sodium (amobarbital) 100 mg/kg, ip.
  • the level of anesthesia is assessed by a steady rhythmic breathing pattern.
  • a 20 mm incision is made through the skin and underlying muscle to expose the left kidney.
  • the kidney is freed of surrounding tissue, exteriorized and two ligatures (3-0 silk) are tied securely around the renal artery and vein proximal to their juncture with the aorta.
  • the renal artery and vein are then severed and the kidney removed.
  • the muscle and skin wounds are closed with 4-0 silk suture and stainless steel wound clips, respectively.
  • a 15 mm incision is made on the back of the neck and a 3-week-release pellet (Innovative Research of America, Sarasota, Florida) containing deoxycorticosterone acetate (100 mg/kg) is implanted subcutaneously.
  • the wound is then closed with stainless-steel clips and both wounds are treated with povidone/iodine; the rats are given a post-surgical intramuscular injection of procaine penicillin G (100,000 U) and buprenorphine (0.05 - 0.1 mg/kg) s.c.
  • the rats are immediately placed on 1 % NaCI + 0.2% KCI drinking water; this treatment continues for at least 3 weeks at which time the animals have become hypertensive and available for experimentation.
  • mice Forty-eight hours prior to experimentation, animals are anesthetized with isoflurane and catheters are implanted in the femoral artery and vein for measuring arterial pressure, collection of blood, and administration of test compounds. Rats are allowed to recover for 48 hours while tethered in a Plexiglas home cage, which also serves as the experimental chamber.
  • Protocols are then set-up on the computer for measurement of blood pressure, heart rate, etc, at predetermined time points.
  • Baseline data are collected at various time points and over various time intervals.
  • baseline or pre-dose values usually consist of data collection and averaging over 3 consecutive, 24-hour time periods prior to drug administration.
  • Blood pressure, heart rate and activity are determined at various pre-selected time points before, during, and after drug administration. All measurements are performed in unrestrained and undisturbed animals. The maximum study time, determined by battery life, could be as long as nine months.
  • SHR are utilized to study the effects of aliskiren in combination with amlodipine and HCTZ
  • the hypertensive background of the SHR is modified either by chronic salt loading in an effort to suppress the renin angiotensin system (RAS) or chronic salt depletion to activate the RAS in the SHR.
  • RAS renin angiotensin system
  • These manipulations will be carried out to more extensively evaluate the efficacy of the various test substances.
  • SHR spontaneously hypertensive rats
  • SHR spontaneously hypertensive rats
  • a radiotelemetric device Data Sciences International, Inc., St. Paul, Minnesota
  • All SHR are allowed to recover from the surgical implantation procedure for at least 2 weeks prior to the initiation of the experiments.
  • Cardiovascular parameters are continuously monitored via the radiotransmitter and transmitted to a receiver where the digitized signal is then collected and stored using a computerized data acquisition system.
  • Blood pressure mean arterial, systolic and diastolic pressure
  • heart rate are monitored in conscious, freely moving and undisturbed SHR in their home cages. The arterial blood pressure and heart rate are measured every 10 minutes for 10 seconds and recorded. Data reported for each rat represent the mean values averaged over a 24 hour period and are made up of the 144-10 minute samples collected each day.
  • the baseline values for blood pressure and heart rate consist of the average of three consecutive 24 hour readings taken prior to initiating the drug treatments. All rats are individually housed in a temperature and humidity controlled room and are maintained on a 12 hour light dark cycle.
  • Vascular function and structure are evaluated after treatment to assess the beneficial effects of the combination.
  • SHR are studied according to the methods described by Intengan HD, Thibault G, Li JS, Schiffrin EL, Circulation 1999, 100 (22): 2267-2275.
  • the methodology for assessing vascular function in DOCA-salt rats is described in Intengan HD, Park JB, Schiffrin, EL, Hypertension, 1999, 34(4 Part 2): 907-913.
  • Drug efficacy for inhibiting diabetic renal disease is assessed in various animal models including spontaneously diabetic (db/db) mice (Ziyadeh F, Hoffman B, Han D, Iglesias-de la Cruz M, Hong S, Isono M, Chen S, McGowan T, Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor- ⁇ antibody in db/db diabetic mice. Proc Natl Acad Sci. 2000;97:8015-8020).
  • the db/db mouse is a widely used model for the renal glomerular lesions seen in non-insulin dependent diabetes (type 2 diabetes).
  • mice are treated daily with vehicle, monotherapy or combination therapy. Every 2 weeks throughout the study urine is collected to measure urinary albumin excretion. At the end of the experiment blood is collected for determining plasma creatinine levels. The kidneys are preserved in situ by perfusion fixation, they are removed and renal pathology is assessed quantitatively by light microscopy and image analysis. Drug efficacy is defined by the reduction (vs vehicle controls) of (i) urinary albumin exretion, (ii) plasma creatinine, and by (iii) the inhibition of renal glomerulosclerosis.
  • Drug efficacy for inhibiting renal fibrosis is assessed in various animal models including the unilateral ureter obstruction model in rats (Ishidoya, S; Morrissey, J; McCracken, R; Reyes, A; Klahr, S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kid Int. 47:1285-1294, 1995).
  • This model involves ligating one ureter, which results in renal fibrosis by 5 days in the kidney drained by that ureter.
  • Drug efficacy is assessed by quantifying with light microscopy and image analysis, the extent of renal fibrosis among treated groups.
  • ACE inhibitors and AT1 receptor blockers inhibit renal fibrosis in this model (Klar, S; Ishidoya, S; Morrissey, J. Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Amer J Kid Dis. 26:141-146, 1995). It can therefore be demonstrated that combination therapy with aliskiren, amlodipine, and HCTZ provides increased protection vs monotherapy.
  • a therapeutically effective amount of each of the components of the combination of the present invention may be administered separately, simultaneously or sequentially and in any order.
  • the unit dose form may also be a fixed combination.
  • the corresponding active ingredient or a pharmaceutically acceptable salt thereof may also be used in form of a hydrate or include other solvents used for crystallization.
  • the pharmaceutical compositions according to the invention can be prepared in a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals (warm-blooded animals), including man, comprising a therapeutically effective amount of the pharmacologically active compound, alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application.
  • Typical oral formulations include tablets, capsules, syrups, elixirs and suspensions.
  • Typical injectable formulations include solutions and suspensions.
  • the invention also relates to combining separate pharmaceutical compositions in kit form. That is a kit combining two or three separate units, e.g. an aliskiren pharmaceutical composition, an amlodipine pharmaceutical composition, and an HCTZ pharmaceutical composition, or in case of two separate units a kit combining a pharmaceutical composition of two of the active agents and a pharmaceutical composition of the remaining active ingredient.
  • kit form is particularly advantageous when the separate components must be administered in different dosage forms (e.g. parenteral aliskiren formulation and oral amlodipine and HCTZ formulations) or are administered at different dosage intervals.
  • the (commercial) product is a commercial package comprising as active ingredients the combination according to the present invention (in the form of two or three separate units of the components (i) to (iii)), together with instructions for its simultaneous, separate or sequential use, or any combination thereof, in the delay of progression or treatment of the diseases mentioned herein.
  • These pharmaceutical preparations are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances.
  • the pharmaceutical preparations consist of from about 0.1 % to 90 %, preferably of from about 1 % to about 80 %, of the active compounds.
  • compositions for enteral or parenteral administration are, for example, in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner which is known per se, for example using conventional mixing, granulation, coating, solubulizing or lyophilizing processes.
  • pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.
  • the dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.
  • Preferred dosages for the active ingredients of the pharmaceutical combination according to the present invention are therapeutically effective dosages, especially those which are commercially available.
  • Aliskiren is supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 1 to about 1 ,000 mg, preferably from about 150 to about 500 mg, of aliskiren which may be applied to patients. Preferably, aliskiren is applied once a day.
  • preferred dosage unit forms are, for example, tablets or capsules comprising e.g. from about 1 mg to about 40 mg, preferably 2.5 to 20 mg daily when administered orally.
  • preferred dosage unit forms are, for example, tablets or capsules comprising e.g. from about 5 mg to about 200 mg, preferably from about 5 mg to about 25 mg, administered orally once a day.
  • the above doses encompass a therapeutically effective amount of the active ingredients of the present invention.
  • An example of a preferred composition comprises an amount of Aliskiren between 140 and 220 mg e.g. 160 mg, an amount of amlodipine between 2 and 12 mg (e.g. 2.5 or 5 or 10 mg) and an amount of HCTZ between 5 and 30 mg, preferably between 5 and 15 (e.g. 12.5 or 6.25 mg).
  • Another example of a preferred composition comprises an amount of Aliskiren between 350 and 550 mg e.g. 450 mg, an amount of amlodipine between 2 and 12 mg (e.g. 2.5 or 5 or 10 mg) and an amount of HCTZ between 5 and 30 mg preferably between 10 and 30 (e.g. 12.5 mg or 25 mg).
  • Another example of a preferred composition comprises an amount of Aliskiren between 550 and 700 mg e.g. 640 mg, an amount of amlodipine between 2 and 12 mg (e.g. 2.5 or 5 or 10 mg) and an amount of HCTZ between 5 and 30 mg preferably between 10 and 30 (e.g. 12.5 mg or 25 mg).

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic and to a method of treatment of a condition or a disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non- diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF, and proliferative diseases of smooth muscle cells, including uterine fibroids comprising administering a therapeutically effective amount of said pharmaceutical composition to a mammal in need of such treatment.

Description

PHARMACEUTICAL COMPOSITION COMPRISING A RENIN INHIBITOR, A CALCIUM CHANNEL
BLOCKER AND A DIURETIC
The renin angiotensin system (RAS) is a complex hormonal system comprised of a large molecular weight precursor, angiotensinogen, two processing enzymes, renin and angiotensin converting enzyme (ACE), and the vasoactive mediator angiotensin II (Ang II) (J. Cardiovasc. Pharmacol., 15(Supp B) (1990) p. S1-S5). The enzyme renin catalyzes the cleavage of angiotensinogen into the decapeptide angiotensin I, which has minimal biological activity on its own and is converted into the active octapeptide Ang II by ACE. Ang II has multiple biological actions on the cardiovascular system, including vasoconstriction, activation of the sympathetic nervous system, stimulation of aldosterone production, antinatriuresis, stimulation of vascular growth (i.e., stimulation of smooth muscle cell proliferation and the deposition of excess extracellular matrix material in the vascular wall), and stimulation of cardiac growth. Ang II functions as a pressor hormone and is involved in the pathophysiology of several forms of hypertension.
The vasoconstrictive effects of angiotensin II are produced by its action on the non- striated smooth muscle cells, the stimulation of the formation of the adrenergenic hormones epinephrine and norepinephrine as well as the increase of the activity of the sympathetic nervous system as a result of the formation of norepinephrine. Angiotensin II also has an influence on electrolyte balance, produces e.g. antinatriuretic and antidiuretic effects in the kidney and thereby promotes the release of, on the one hand, the vasopressin peptide from the pituitary gland and, on the other hand, of aldosterone from the adrenal glomerulosa. All these influences play an important part in the regulation of blood pressure, in increasing both circulating volume and peripheral resistance. Angiotensin II is also involved in cell growth and migration and in extracellular matrix formation.
Angiotensin II interacts with specific receptors on the surface of the target cell. It has been possible to identify receptor subtypes that are termed e.g. AT1- and AT 2-receptors. In recent times great efforts have been made to identify substances that bind to the AT1 - receptor. Such active ingredients are often termed angiotensin II antagonists. Because of the inhibition of the AT1 -receptor such antagonists can be used e.g. as antihypertensives or for the treatment of congestive heart failure, among other indications. Angiotensin II antagonists are therefore understood to be those active ingredients that bind to the AT1- receptor subtype.
Inhibitors of the renin angiotensin system are well known drugs that lower blood pressure and exert beneficial actions in hypertension and in congestive heart failure as described, for example, in N. Eng. J. Med. 316, 23 (1987) p. 1429-1435. A large number of peptide and non-peptide inhibitors of the renin angiotensin system are known, the most widely studied being the ACE inhibitors, which include the drugs captopril, enalapril, lisinopril, benazepril and spirapril. Although a major mode of action of ACE inhibitors involves prevention of formation of the vasoconstrictor peptide Ang II, it has been reported in Hypertension, 16, 4 (1990) p. 363-370 that ACE cleaves a variety of peptide substrates, including the vasoactive peptides bradykinin and substance P. Prevention of the degradation of bradykinin by ACE inhibitors has been demonstrated, and the activity of the ACE inhibitors in some conditions has been reported in Circ. Res., 66, 1 (1990) p. 242-248 to be mediated by elevation of bradykinin levels rather than inhibition of Ang II formation. Consequently, it cannot be presumed that the effect of an ACE inhibitor is due solely to prevention of angiotensin formation and subsequent inhibition of the renin angiotensin system. In addition to inhibiting the conversion of angiotensin I to angiotensin II, or blocking the AT1 receptor, the RAS can be stopped at the beginning of its pathway. This initial step (i.e., the conversion of angiotensinogen to angiotensin I) is mediated by renin and can be inhibited by renin inhibitors (Rl). Renin inhibitors fully shut down the formation of angiotensin II because they act on the rate-limiting step in the cascade. Because of the virtually complete blockage of angiotensin II formation with Rl, these agents can be demonstrated to have improved efficacy over ACE inhibitors or blockers of the AT1 receptor. Furthermore, because of their high degree of specificity, Rl are associated with less side effects than ACE inhibitors. One such Rl is aliskiren. Others are detikiren, terlakiren, and zankiren.
Aliskiren has the following chemical formula (I):
Figure imgf000004_0001
The renin inhibitor of formula (I), chemically defined as 2(S),4(S),5(S),7(S)-N-(3-amino-2,2- dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy- propoxy)phenyl]-octanamide, is specifically disclosed in EP 678503 A. Especially preferred is the hemi-fumarate salt thereof.
A drawback in the treatment of hypertension and diseases and conditions related thereto is that monotherapy frequently stimulates compensatory reflexes that counteract the pharmacologically-induced reduction in blood pressure. This compensation tends to hinder successful blood pressure lowering. It is therefore desirable to develop additional means of treatment for this application.
The present invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic, or, where appropriate, in each case a pharmaceutically acceptable salt thereof, especially for the treatment of a disease or condition as set forth hereinbefore or hereinafter.
The invention likewise relates to the use of (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic, or, where appropriate, in each case a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease or condition as set forth hereinbefore or hereinafter.
The invention likewise relates to a method for the treatment of a disease or conditions as set forth hereinbefore or hereinafter comprising administering to an animal, including man, a therapeutically effective amount of (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic, or, where appropriate, in each case a pharmaceutically acceptable salt thereof.
The present invention furthermore relates to a kit of parts comprising
(i) a pharmaceutical composition of a renin inhibitor or a pharmaceutically acceptable salt thereof, (ii ) a pharmaceutical composition of a calcium channel blocker (CCB) or a pharmaceutically acceptable salt thereof, and (iii ) a pharmaceutical composition of a diuretic, or a pharmaceutically acceptable salt thereof, in the form of two or three separate units of the components (i) to (iii).
According to the invention the renin inhibitor (i) is selected from the group consisting of aliskiren, detikiren, terlakiren, and zankiren; (ii) the CCB is selected from the group consisting of amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, niguldipine, niludipine, nimodipine, nisoldipine, nitrendipine, nivaldipine, ryosidine, anipamil, diltiazem, fendiline, flunarizine, gallopamil, mibefradil, prenylamine, tiapamil and verapamil; and the diuretic (iii) is selected from the group consisting of bumetanide, ethacrynic acid, furosemide, torsemide, amiloride, spironolactone, triamterene, chlorothalidone, chlorothiazide, hydrochlorothiazide, hydroflumthiazide, methylchlothiazide, metolazone, and dichlorphenamide and also amiloride. In each case where appropriate, e.g. if the compound is not present as a pharmaceutically acceptable salt per se as in the case of hydrochlorothiazide, these compounds also include their pharmaceutically acceptable salts.
The structure of the active agents identified by generic or tradenames may be taken from the actual edition of the standard compendium 'The Merck Index" or from databases, e.g. LifeCycle Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled to identify the active agents and, based on these references, likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models, both in vitro and in vivo.
The present invention further relates to the above pharmaceutical composition for the treatment of heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter or detrimental vascular remodeling. It can further be shown that combination therapy with the inventive combination and in particular with aliskiren, especially the hemi-fumarate salt thereof, amlodipine, especially the maleate or more preferably the besylate thereof, and hydrochlorthiazide (HCTZ) proves to be beneficial in the treatment and prevention of myocardial infarction and its sequelae. Such a combination therapy is also useful in treating atherosclerosis, angina (whether stable or unstable), and renal insufficiency (diabetic and non-diabetic). Furthermore, such a combination therapy can improve endothelial dysfunction, thereby providing benefit in diseases in which normal endothelial function is disrupted such as heart failure, angina pectoris and diabetes. Furthermore, the combination of the present invention may be used for the treatment or prevention of secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF-β and proliferative diseases of smooth muscle cells (such as uterine fibroids).
The present invention furthermore relates to a method of treatment of a condition or a disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non- diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF, and proliferative diseases of smooth muscle cells, including uterine fibroids comprising administering a therapeutically effective amount of a combination of (i) a renin inhibitor, (ii) a CCB, and (iii) a diuretic, or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier to a mammal in need of such treatment. Preferably, the renin ihibitor is aliskiren, the CCB is amlodipine, and the diuretic is HCTZ.
The invention likewise relates to the use of a combination of (i) a renin inhibitor, (ii) a CCB, and (iii) a diuretic, or pharmaceutically acceptable salts for the treatmeno of a disease or condition as described hereinbefore or hereinafter.
As used throughout the specification and in the claims, the term "treatment" embraces all the different forms or modes of treatment as known to those of the pertinent art and in particular includes preventive, curative and palliative treatment.
Diuretic activates the RAS, thus makes inhibition of RAS by renin inhibitor (Rl) more effective. Addition of CCB to Rl, whose activity is potentiated by diuretic, will lower e.g. blood pressure by a mechanism separate from RAS. CCB has been shown to be renoprotective at least in part through (i) inhibition of glomerular expression of TGF-beta & alpha-smooth muscle cell actin (Nephron 2000 Nov;86(3):315-26) and (ii) exerting growth- inhibitory activity through inhibiting multiple cell signal pathways (J Hypertens 2002 Jan;20(1):95-102).
Surprisingly it was found that using the inventive combination of divergent mechanisms maximizes the chance to avoid the activation of compensatory blood pressure regulating mechanisms that are stimulated with mono-therapy anti-hypertensive treatment. Unexpectedly, blocking the RAS is most effective when the system is activated. Thus, it is possible to achieve greater pharmacological inhibition of the RAS when blockers of this system are administered simultaneously with mild activators of the RAS. Such activation of the RAS can be accomplished with the calcium channel blockers and diuretics. In addition, each of these therapies alone is antihypertensive. The use of an Rl in this combination provides the most effective and complete blockage of the RAS. The unexpected advantage of a triple vs dual combination is the (i) potentiated blod pressure lowering effect and (ii) more effective anti-proliferative effect through the combined actions of rennin inhibition (potentiated by diuretic) and CCB. Both of these activities are translated into enhanced tissue protection. The improved activity and benefit over dual combo results from a potentiation or even synergistic interactions between 3 components. Furthermore, less side effects are can be manifested by the ability to use lower doses of the partners to be combined. For example, doses of individual components can be reduced by 2-7 fold or reduced by 3-7, 4-7, 5-7 or 6-7 fold, when given in combination and still achieve comparable blood pressure lowering activity compared to each individual agent. In humans, the superiority or surprising advantages of triple over dual combos can be demonstrated e.g. by testing of the combination for benefits on blood pressure lowering, left ventricular hypertrophy, renal protection (e.g., reversing, ameliorating, or delaying worsening of proteinuria; slowing decline in glomerular filtration rate or creatinine clearance, delay doubling of serum creatinine).
Prolonged and uncontrolled hypertensive vascular disease ultimately leads to a variety of pathological changes in target organs such as the heart and kidney. The presence of diabetes exacerbates these changes. Sustained hypertension can lead as well to an increased occurrence of stroke. Therefore, there is a strong need to evaluate the efficacy of antihypertensive therapy, an examination of additional cardiovascular endpoints, beyond those of blood pressure lowering, to get further insight into the benefits of combined treatment. The nature of hypertensive vascular diseases is multifactorial. Under certain circumstances, drugs with different mechanisms of action have been combined. However, simply using any combination of drugs having different modes of action does not necessarily lead to combinations with advantageous effects.
Potentiation is the enhancement of the biological effect of one agent by another agent to produce either an additive or greater than additive biological effect, compared to the effects from the individual agents, while synergism is the enhancement of the biological effect of One agent by another agent to produce a biological effect that is greater than that predicted by adding the effects of the individual components.
In one aspect the present invention relates to a pharmaceutical composition comprising (i) aliskiren, (ii) amlodipine , and (ii) hydrochlorothiazide (HCTZ) or pharmaceutically effective salts thereof.
In another embodiment the present invention relates to methods of treating cardiac and renal related conditions by administration of the pharmaceutical composition comprising (i) aliskiren, especially the hemi-fumarate salt thereof, amlodipine, especially the maleate or more preferably the besylate thereof, and HCTZ.
The compounds to be combined can be present as pharmaceutically acceptable salts. If these compounds have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds having at least one acid group (for example COOH) can also form salts with bases. Corresponding internal salts may furthermore be formed, if a compound comprises e.g. both a carboxy and an amino group.
It has surprisingly been found that a combination of aliskiren, amlodipine, and HCTZ achieves greater therapeutic effect than the administration of each of these agents alone. Greater efficacy can also be documented as a prolonged duration of action. The duration of action can be monitored as either the time to return to baseline prior to the next dose or as the area under the curve (AUC) and is expressed as the product of the change in blood pressure in millimeters of mercury (change in mmHg) and the duration of the effect (minutes, hours or days).
Further benefits are that lower doses of the individual drugs to be combined according to the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used to diminish the incidence of side effects. The combined administration of aliskiren, amlodipine, and HCTZ or pharmaceutically acceptable salts thereof results in a significant response in a greater percentage of treated patients, that is, a greater responder rate results, regardless of the underlying etiology of the condition. This is in accordance with the desires and requirements of the patients to be treated.
It can be shown that combination therapy with aliskiren, especially the hemi-fumarate salt thereof, amlodipine, especially the maleate or more preferably the besylate thereof, and HCTZ results in a more effective antihypertensive therapy (whether for malignant, essential, reno-vascular, diabetic, isolated systolic, or other secondary type of hypertension) through improved efficacy as well as a greater responder rate. The combination is also useful in the treatment or prevention of heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter or detrimental vascular remodeling. It can further be shown that combination therapy with aliskiren, amlodipine, and HCTZ proves to be beneficial in the treatment and prevention of myocardial infarction and its sequelae. A combination therapy with aliskiren, amlodipine, and HCTZ is also useful in treating atherosclerosis, angina (whether stable or unstable), and renal insufficiency (diabetic and non-diabetic). Furthermore, combination therapy using aliskiren, amlodipine, and HCTZ can improve endothelial dysfunction, thereby providing benefit in diseases in which normal endothelial function is disrupted such as heart failure, angina pectoris and diabetes. Furthermore, the combination of the present invention may be used for the treatment or prevention of secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF-β and proliferative diseases of smooth muscle cells (such as uterine fibroids).
The person skilled in the pertinent art is fully enabled to select a relevant test model to prove the efficacy of a combination of the present invention in the hereinbefore and hereinafter indicated therapeutic indications. Representative studies are carried out with a combination of aliskiren, especially the hemi-fumarate salt thereof, amlodipine, especially the maleate or more preferably the besylate thereof, and HCTZ applying the following methodology.
The advantages of the present combinations are, for example, demonstrated in a clinical study or in the test procedure as essentially described hereinafter. Many clinical study protocols adapted to test our combinations are known by the person skilled in the art. An example of a clinical trial useful to demonstrate the unexpected advantages of our new combinations is described by Nussberger J. et al. (Hypertension 2002 Jan;39(1):E1-8). The same protocol is performed with our preferred combinations such as described herein. This protocol is hereby incorporated into the present application by reference to this publications. Drug efficacy is assessed in various animal models including those found below, using the following approximate dosages. Aliskiren is administered in subcutaneously implanted osmotic minipumps at approximately 1-200 mg/kg/day (monotherapy), and approximately 1- 75 mg kg/day (combination therapy). Amlodipine and HCTZ are administered orally in dosages below 75 mg/kg/day as mono- or combination therapy.
Among the animal models used to assess drug efficacy are the deoxycorticosterone acetate - salt rat (DOCA-salt) and the spontaneously hypertensive rat (SHR) models, either maintained on a normal salt diet or with salt loading (4-8% salt in rat chow or 1% NaCI as drinking water). The DOCA-salt test model utilizes either an acute or chronic study protocol. An acute study procedure involves assessment of the effects of various test substances over a six-hour experimental period using rats with indwelling femoral arterial and venous catheters. The Acute Study Procedure evaluates test substances for their ability to reduce blood pressure during the established phase of DOCA-salt hypertension. In contrast, the Chronic Study Procedure assesses the ability of test substances to prevent or delay the rise in blood pressure during the development phase of DOCA-salt hypertension. Therefore, blood pressure will be monitored in the chronic study procedure by means of a radiotransmitter. The radiotransmitter is surgically implanted into the abdominal aorta of rats, prior to the initiation of DOCA-salt treatment and thus, prior to the induction of hypertension. Blood pressure is chronically monitored for periods of up 6 weeks (approximately one week prior to DOCA-salt administration and for 5 weeks thereafter).
Rats are anesthetized with 2-3% isoflurane in oxygen inhalant followed by Amytal sodium (amobarbital) 100 mg/kg, ip. The level of anesthesia is assessed by a steady rhythmic breathing pattern.
Acute study procedure:
Rats undergo a unilateral nephrectomy at the time of DOCA implantation. Hair is clipped on the left flank and the back of the neck and scrubbed with sterile alcohol swabs and povidone/iodine. During surgery rats are placed on a heating pad to maintain body temperature at 37 degrees C.
A 20 mm incision is made through the skin and underlying muscle to expose the left kidney. The kidney is freed of surrounding tissue, exteriorized and two ligatures (3-0 silk) are tied securely around the renal artery and vein proximal to their juncture with the aorta. The renal artery and vein are then severed and the kidney removed. The muscle and skin wounds are closed with 4-0 silk suture and stainless steel wound clips, respectively. At the same time, a 15 mm incision is made on the back of the neck and a 3-week-release pellet (Innovative Research of America, Sarasota, Florida) containing deoxycorticosterone acetate (100 mg/kg) is implanted subcutaneously. The wound is then closed with stainless-steel clips and both wounds are treated with povidone/iodine; the rats are given a post-surgical intramuscular injection of procaine penicillin G (100,000 U) and buprenorphine (0.05 - 0.1 mg/kg) s.c. The rats are immediately placed on 1 % NaCI + 0.2% KCI drinking water; this treatment continues for at least 3 weeks at which time the animals have become hypertensive and available for experimentation.
Forty-eight hours prior to experimentation, animals are anesthetized with isoflurane and catheters are implanted in the femoral artery and vein for measuring arterial pressure, collection of blood, and administration of test compounds. Rats are allowed to recover for 48 hours while tethered in a Plexiglas home cage, which also serves as the experimental chamber.
Chronic study procedure:
This procedure is the same as above except that rats are implanted with a radiotransmitter, 7-10 days prior to the unilateral nephrectomy and initiation of DOCA and salt. In addition, rats do not undergo surgery for placement of femoral arterial and venous catheters. Radiotransmitters are implanted as described in M.K. Bazil, C. Krulan and R.L. Webb., Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats, J.Cardiovasc. Pharmacol. 22: 897-905, 1993.
Protocols are then set-up on the computer for measurement of blood pressure, heart rate, etc, at predetermined time points. Baseline data are collected at various time points and over various time intervals. For example, baseline or pre-dose values usually consist of data collection and averaging over 3 consecutive, 24-hour time periods prior to drug administration.
Blood pressure, heart rate and activity are determined at various pre-selected time points before, during, and after drug administration. All measurements are performed in unrestrained and undisturbed animals. The maximum study time, determined by battery life, could be as long as nine months.
Additionally, SHR are utilized to study the effects of aliskiren in combination with amlodipine and HCTZ The hypertensive background of the SHR is modified either by chronic salt loading in an effort to suppress the renin angiotensin system (RAS) or chronic salt depletion to activate the RAS in the SHR. These manipulations will be carried out to more extensively evaluate the efficacy of the various test substances. For experiments performed in spontaneously hypertensive rats (SHR), these animals are supplied by Taconic Farms, Germantown, New York (Tac:N(SHR)fBR). A radiotelemetric device (Data Sciences International, Inc., St. Paul, Minnesota) is implanted into the lower abdominal aorta of all test animals between the ages of 14 to 16 weeks of age. All SHR are allowed to recover from the surgical implantation procedure for at least 2 weeks prior to the initiation of the experiments. Cardiovascular parameters are continuously monitored via the radiotransmitter and transmitted to a receiver where the digitized signal is then collected and stored using a computerized data acquisition system. Blood pressure (mean arterial, systolic and diastolic pressure) and heart rate are monitored in conscious, freely moving and undisturbed SHR in their home cages. The arterial blood pressure and heart rate are measured every 10 minutes for 10 seconds and recorded. Data reported for each rat represent the mean values averaged over a 24 hour period and are made up of the 144-10 minute samples collected each day. The baseline values for blood pressure and heart rate consist of the average of three consecutive 24 hour readings taken prior to initiating the drug treatments. All rats are individually housed in a temperature and humidity controlled room and are maintained on a 12 hour light dark cycle.
In addition to the cardiovascular parameters, weekly determinations of body weight also are recorded in all rats. Treatments are administered in the drinking water, via daily oral gavage or in osmotic minipumps as stated above. If given in drinking water, water consumption is measured five times per week. Doses of drugs for individual rats are then calculated based on water consumption for each rat, the concentration of drug substance in the drinking water, and individual body weights. All drug solutions in the drinking water are made up fresh every three to four days. Upon completion of the chronic studies, SHR or DOCA-salt rats are anesthetized and the heart rapidly removed. After separation and removal of the atrial appendages, left ventricle and left plus right ventricle (total) are weighed and recorded. Left ventricular and total ventricular mass are then normalized to body weight and reported. All values reported for blood pressure and cardiac mass represent the group mean + sem.
Vascular function and structure are evaluated after treatment to assess the beneficial effects of the combination. SHR are studied according to the methods described by Intengan HD, Thibault G, Li JS, Schiffrin EL, Circulation 1999, 100 (22): 2267-2275. Similarly, the methodology for assessing vascular function in DOCA-salt rats is described in Intengan HD, Park JB, Schiffrin, EL, Hypertension, 1999, 34(4 Part 2): 907-913.
Drug efficacy for inhibiting diabetic renal disease is assessed in various animal models including spontaneously diabetic (db/db) mice (Ziyadeh F, Hoffman B, Han D, Iglesias-de la Cruz M, Hong S, Isono M, Chen S, McGowan T, Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci. 2000;97:8015-8020). The db/db mouse is a widely used model for the renal glomerular lesions seen in non-insulin dependent diabetes (type 2 diabetes). Mice are treated daily with vehicle, monotherapy or combination therapy. Every 2 weeks throughout the study urine is collected to measure urinary albumin excretion. At the end of the experiment blood is collected for determining plasma creatinine levels. The kidneys are preserved in situ by perfusion fixation, they are removed and renal pathology is assessed quantitatively by light microscopy and image analysis. Drug efficacy is defined by the reduction (vs vehicle controls) of (i) urinary albumin exretion, (ii) plasma creatinine, and by (iii) the inhibition of renal glomerulosclerosis.
Drug efficacy for inhibiting renal fibrosis is assessed in various animal models including the unilateral ureter obstruction model in rats (Ishidoya, S; Morrissey, J; McCracken, R; Reyes, A; Klahr, S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kid Int. 47:1285-1294, 1995). This model involves ligating one ureter, which results in renal fibrosis by 5 days in the kidney drained by that ureter. Drug efficacy is assessed by quantifying with light microscopy and image analysis, the extent of renal fibrosis among treated groups. ACE inhibitors and AT1 receptor blockers inhibit renal fibrosis in this model (Klar, S; Ishidoya, S; Morrissey, J. Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Amer J Kid Dis. 26:141-146, 1995). It can therefore be demonstrated that combination therapy with aliskiren, amlodipine, and HCTZ provides increased protection vs monotherapy.
A therapeutically effective amount of each of the components of the combination of the present invention may be administered separately, simultaneously or sequentially and in any order. The unit dose form may also be a fixed combination.
The corresponding active ingredient or a pharmaceutically acceptable salt thereof may also be used in form of a hydrate or include other solvents used for crystallization. The pharmaceutical compositions according to the invention can be prepared in a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals (warm-blooded animals), including man, comprising a therapeutically effective amount of the pharmacologically active compound, alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application. Typical oral formulations include tablets, capsules, syrups, elixirs and suspensions. Typical injectable formulations include solutions and suspensions.
The invention also relates to combining separate pharmaceutical compositions in kit form. That is a kit combining two or three separate units, e.g. an aliskiren pharmaceutical composition, an amlodipine pharmaceutical composition, and an HCTZ pharmaceutical composition, or in case of two separate units a kit combining a pharmaceutical composition of two of the active agents and a pharmaceutical composition of the remaining active ingredient. The kit form is particularly advantageous when the separate components must be administered in different dosage forms (e.g. parenteral aliskiren formulation and oral amlodipine and HCTZ formulations) or are administered at different dosage intervals.
In a preferred embodiment, the (commercial) product is a commercial package comprising as active ingredients the combination according to the present invention (in the form of two or three separate units of the components (i) to (iii)), together with instructions for its simultaneous, separate or sequential use, or any combination thereof, in the delay of progression or treatment of the diseases mentioned herein. These pharmaceutical preparations are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances. For example, the pharmaceutical preparations consist of from about 0.1 % to 90 %, preferably of from about 1 % to about 80 %, of the active compounds. Pharmaceutical preparations for enteral or parenteral administration are, for example, in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner which is known per se, for example using conventional mixing, granulation, coating, solubulizing or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.
The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.
Preferred dosages for the active ingredients of the pharmaceutical combination according to the present invention are therapeutically effective dosages, especially those which are commercially available.
Aliskiren is supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 1 to about 1 ,000 mg, preferably from about 150 to about 500 mg, of aliskiren which may be applied to patients. Preferably, aliskiren is applied once a day.
In case of amlodipine, preferred dosage unit forms are, for example, tablets or capsules comprising e.g. from about 1 mg to about 40 mg, preferably 2.5 to 20 mg daily when administered orally. In case of HCTZ, preferred dosage unit forms are, for example, tablets or capsules comprising e.g. from about 5 mg to about 200 mg, preferably from about 5 mg to about 25 mg, administered orally once a day. The above doses encompass a therapeutically effective amount of the active ingredients of the present invention. An example of a preferred composition comprises an amount of Aliskiren between 140 and 220 mg e.g. 160 mg, an amount of amlodipine between 2 and 12 mg (e.g. 2.5 or 5 or 10 mg) and an amount of HCTZ between 5 and 30 mg, preferably between 5 and 15 (e.g. 12.5 or 6.25 mg).
Another example of a preferred composition comprises an amount of Aliskiren between 350 and 550 mg e.g. 450 mg, an amount of amlodipine between 2 and 12 mg (e.g. 2.5 or 5 or 10 mg) and an amount of HCTZ between 5 and 30 mg preferably between 10 and 30 (e.g. 12.5 mg or 25 mg).
Another example of a preferred composition comprises an amount of Aliskiren between 550 and 700 mg e.g. 640 mg, an amount of amlodipine between 2 and 12 mg (e.g. 2.5 or 5 or 10 mg) and an amount of HCTZ between 5 and 30 mg preferably between 10 and 30 (e.g. 12.5 mg or 25 mg).

Claims

What is claimed is:
1. A pharmaceutical composition comprising (i) a renin inhibitor,
(ii) a calcium channel blocker (CCB), and (iii) a diuretic.
2. A pharmaceutical composition according to claim 1 , wherein the renin inhibitor (i) is selected from the group consisting of aliskiren, detikiren, terlakiren, and zankiren; the CCB (ii) is selected from the group consisting of amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, niguldipine, niludipine, nimodipine, nisoldipine, nitrendipine, nivaldipine, ryosidine, anipamil, diltiazem, fendiline, flunarizine, gallopamil, mibefradil, prenylamine, tiapamil and verapamil; and the diuretic (iii) is selected from the group consisting of bumetanide, ethacrynic acid, furosemide, torsemide, amiloride, spironolactone, triamterene, chlorothalidone, chlorothiazide, hydrochlorothiazide, hydroflumthiazide, methylchlothiazide, metolazone, and dichlorphenamide.
3. A pharmaceutical composition according to claim 1 or 2, wherein the renin inhibitor (i) is aliskiren, the CCB (ii) is amlodipine, and the diuretic (iii) is hydrochlorothiazide.
4. A pharmaceutical composition according to claim 3 containing aliskiren in an amount in the range from 1 to 1 ,000 mg, amlodipine in an amount in the range from 1 to 40 mg, and hydrochlorothiazide in an amount in the range from 5 to 200 mg.
5. A pharmaceutical composition according to claim 3 containing aliskiren in an amount in the range from 140 to 550 mg, amlodipine in an amount in the range from 2 to 12 mg, and hydrochlorothiazide in an amount in the range from 5 to 30 mg.
6. Method of treatment of a condition or a disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non- diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF, and proliferative diseases of smooth muscle cells, including uterine fibroids comprising administering a therapeutically effective amount of a pharmaceutical composition according to any one of claims 1 to 4 to a mammal in need of such treatment.
7. The use of a combination according to any one of claims 1 to 5 for the manufacture of a medicament for the treatment of a condition or a disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non- diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF, and proliferative diseases of smooth muscle cells, including uterine fibroids.
8. The use of a combination according to any one of claims 1 to 5 for the treatment of a condition or a disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non- diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF, and proliferative diseases of smooth muscle cells, including uterine.
9. A commercial package comprising
(i) a renin inhibitor or a pharmaceutically acceptable salt thereof,
(ii ) a calcium channel blocker (CCB) or a pharmaceutically acceptable salt thereof, and
(iii ) a diuretic, or a pharmaceutically acceptable salt thereof, in the form of two or three separate units of the components (i) to (iii), together with instructions for simultaneous, separate or sequential use thereof in the delay of progression or treatment of a condition or disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non- diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF, and proliferative diseases of smooth muscle cells, including uterine.
10. A commercial package according to claim 9, wherein the renin inhibitor (i) is aliskiren, the CCB (ii) is amlodipine and the diuretic (iii) is hydrochlorothiazide.
11. A kit of parts comprising
(i) a pharmaceutical composition of a renin inhibitor,
(ii) a pharmaceutical composition of a calcium channel blocker (CCB), and
(iii) a pharmaceutical composition of a diuretic in the form of two or three separate units of the components (i) to (iii).
12. A kit of parts according to claim 11 , wherein the renin inhibitor (i) is selected from the group consisting of aliskiren, detikiren, terlakiren, and zankiren; the CCB (ii) is selected from the group consisting of amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, niguldipine, niludipine, nimodipine, nisoldipine, nitrendipine, nivaldipine, ryosidine, anipamil, diltiazem, fendiline, flunarizine, gallopamil, mibefradil, prenylamine, tiapamil and verapamil; and the diuretic (iii) is selected from the group consisting of bumetanide, ethacrynic acid, furosemide, torsemide, amiloride, spironolactone, triamterene, chlorothalidone, chlorothiazide, hydrochlorothiazide, hydroflumthiazide, methylchlothiazide, metolazone, and dichlorphenamide.
13. A kit of parts according to claim 11 , wherein the renin inhibitor (i) is aliskiren, the CCB (ii) is amlodipine, and the diuretic (iii) is hydrochlorothiazide.
14. A kit of parts according to claim 11 , wherein aliskiren in an amount in the range from 1 to 1 ,000 mg, amlodipine in an amount in the range from 1 to 40 mg, and hydrochlorothiazide in an amount in the range from 5 to 200 mg.
15. A kit of parts according to claim 11 , wherein aliskiren in an amount in the range from 140 to 550 mg, amlodipine in an amount in the range from 2 to 12 mg, and hydrochlorothiazide in an amount in the range from 5 to 30 mg.
PCT/EP2003/005188 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic WO2003097098A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
AT03730064T ATE520417T1 (en) 2002-05-17 2003-05-16 PHARMACEUTICAL COMPOSITION CONTAINING A RENIN INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETIC
JP2004505094A JP5288678B2 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
CA2485081A CA2485081C (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
KR10-2004-7018479A KR20050008717A (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
AU2003240669A AU2003240669B2 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
US10/514,683 US20050182042A1 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
BR0310084-7A BR0310084A (en) 2002-05-17 2003-05-16 A pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic.
NZ536555A NZ536555A (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
DK03730064.7T DK1507558T3 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
EP03730064A EP1507558B8 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
KR1020137023159A KR20130109244A (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
MXPA04011383A MXPA04011383A (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic.
SI200332071T SI1507558T1 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
IL164837A IL164837A (en) 2002-05-17 2004-10-25 Pharmaceutical compositions comprising aliskiren, amlodipine and hydrochlorothiazide and kit comprising the same
NO20045459A NO334382B1 (en) 2002-05-17 2004-12-15 A pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic, its use, a commercial package and a set of parts comprising this
HK05106985.9A HK1074774A1 (en) 2002-05-17 2005-08-12 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
US12/188,604 US8183295B2 (en) 2002-05-17 2008-08-08 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
US13/307,567 US20120071470A1 (en) 2002-05-17 2011-11-30 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
LU92000C LU92000I2 (en) 2002-05-17 2012-05-14 A combination comprising aliskiren or a pharmaceutically acceptable salt thereof and amlodipine or a pharmaceutically acceptable salt thereof and hydrochlorothiazide or a pharmaceutically acceptable salt thereof
CY2012011C CY2012011I2 (en) 2002-05-17 2012-05-14 PHARMACEUTICAL PREPARATION CONTAINING A RENIN INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETIC

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38154602P 2002-05-17 2002-05-17
US60/381,546 2002-05-17

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/514,683 A-371-Of-International US20050182042A1 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
US10514683 A-371-Of-International 2003-05-16
US12/188,604 Continuation US8183295B2 (en) 2002-05-17 2008-08-08 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic

Publications (1)

Publication Number Publication Date
WO2003097098A1 true WO2003097098A1 (en) 2003-11-27

Family

ID=29550141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005188 WO2003097098A1 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic

Country Status (25)

Country Link
US (3) US20050182042A1 (en)
EP (2) EP1507558B8 (en)
JP (2) JP5288678B2 (en)
KR (3) KR20050008717A (en)
CN (1) CN1655819A (en)
AT (1) ATE520417T1 (en)
AU (1) AU2003240669B2 (en)
BR (1) BR0310084A (en)
CA (1) CA2485081C (en)
CY (2) CY1112013T1 (en)
DK (1) DK1507558T3 (en)
EC (1) ECSP045428A (en)
ES (1) ES2369216T3 (en)
HK (1) HK1074774A1 (en)
IL (1) IL164837A (en)
LU (1) LU92000I2 (en)
MX (1) MXPA04011383A (en)
NO (1) NO334382B1 (en)
NZ (1) NZ536555A (en)
PL (1) PL219032B1 (en)
PT (1) PT1507558E (en)
RU (1) RU2316318C2 (en)
SI (1) SI1507558T1 (en)
WO (1) WO2003097098A1 (en)
ZA (1) ZA200408442B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077418A1 (en) * 2004-02-17 2005-08-25 Novartis Ag Combination of renin inhibitor and diuretics
WO2005089731A2 (en) * 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
WO2006086456A2 (en) * 2005-02-11 2006-08-17 Novartis Ag Combination of organic compounds
WO2007056324A2 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2007147596A1 (en) * 2006-06-23 2007-12-27 Novartis Ag Galenical formulations of aliskiren and hydrochlorothiazide
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
WO2008098992A1 (en) * 2007-02-16 2008-08-21 Novartis Ag Use of organic compounds
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
JP2008538549A (en) * 2005-03-22 2008-10-30 ノバルティス アクチエンゲゼルシャフト Biomarkers on the effectiveness of aliskiren as a hypertensive agent
US7732467B2 (en) 2003-05-15 2010-06-08 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
US8236347B2 (en) 2007-10-05 2012-08-07 Alzheimer's Institute Of America, Inc. Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis
US8613949B2 (en) 2008-09-22 2013-12-24 Novartis Ag Galenical formulations of organic compounds
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11096918B2 (en) 2005-11-09 2021-08-24 Novartis Pharmaceuticals Corporation Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
ES2369216T3 (en) * 2002-05-17 2011-11-28 Novartis Pharma Ag PHARMACEUTICAL COMPOSITION THAT INCLUDES A RHININE INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETTIC.
PE20142101A1 (en) * 2004-03-17 2014-12-27 Novartis Ag PHARMACEUTICAL COMPOSITIONS OF ALISKIREN
JP2010508370A (en) * 2006-11-07 2010-03-18 ノバルティス アーゲー Crystal form of aliskiren hemifumarate
US20100130616A1 (en) * 2006-11-09 2010-05-27 Novartis Ag Salt of aliskiren with orotic acid
EP2094289B1 (en) * 2006-12-04 2013-03-13 Promedior, Inc. Combination of sap and enalapril for use in the treatment of fibrotic or fibroproliferative disorders
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
SI2189442T1 (en) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
JP5980508B2 (en) * 2009-03-11 2016-08-31 プロメディオール， インコーポレイテッド Treatment methods for autoimmune disorders
PT2405928T (en) * 2009-03-11 2017-02-07 Promedior Inc Treatment and diagnostic methods for hypersensitive disorders
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
PL2987803T3 (en) 2009-06-17 2019-04-30 Promedior Inc Sap variants and their use
CN102247344A (en) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 Novel blood pressure reducing composition
CN102552277A (en) * 2011-12-02 2012-07-11 邬林祥 Amlodipine, aliskiren and hydrochlorothiazide compound antihypertensive medicine
CN102626391B (en) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 Aliskiren-hydrochlorothiazide drug combination liposome solid preparation
GB201317373D0 (en) 2013-10-01 2013-11-13 Univ Dundee Treatment and prevention of cancer
CN111789843A (en) * 2019-04-08 2020-10-20 深圳奥萨医药有限公司 Pharmaceutical composition containing amlodipine, chlorthalidone and amiloride
KR102414285B1 (en) * 2020-06-02 2022-06-28 이화여자대학교 산학협력단 Pharmaceutical composition for prevention or treatment of bone disease containing Flunarizine or pharmaceutically acceptable salts thereof as an active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010097A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
WO2002040007A1 (en) * 2000-11-17 2002-05-23 Novartis Ag Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
WO2002043807A2 (en) * 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5114925A (en) * 1991-01-22 1992-05-19 Merck & Co., Inc. Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0795327A1 (en) 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
ATE401082T1 (en) * 2001-09-11 2008-08-15 Asahi Kasei Pharma Corp MEDICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CEREBROVASCULAR DISORDERS
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
ES2369216T3 (en) * 2002-05-17 2011-11-28 Novartis Pharma Ag PHARMACEUTICAL COMPOSITION THAT INCLUDES A RHININE INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETTIC.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010097A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
WO2002040007A1 (en) * 2000-11-17 2002-05-23 Novartis Ag Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
WO2002043807A2 (en) * 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US7732467B2 (en) 2003-05-15 2010-06-08 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
WO2005077418A1 (en) * 2004-02-17 2005-08-25 Novartis Ag Combination of renin inhibitor and diuretics
AU2005224014B9 (en) * 2004-03-17 2009-08-27 Novartis Ag Use of organic compounds
EP1977741A3 (en) * 2004-03-17 2009-10-14 Novartis AG Use of renin inhibitors in therapy
WO2005089731A3 (en) * 2004-03-17 2006-05-11 Novartis Ag Use of renin inhibitors in therapy
AU2005224014B2 (en) * 2004-03-17 2009-07-16 Novartis Ag Use of organic compounds
WO2005089731A2 (en) * 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
WO2006086456A3 (en) * 2005-02-11 2007-11-15 Novartis Ag Combination of organic compounds
AU2006212772B2 (en) * 2005-02-11 2009-06-11 Novartis Ag Combination of organic compounds
WO2006086456A2 (en) * 2005-02-11 2006-08-17 Novartis Ag Combination of organic compounds
JP2008538549A (en) * 2005-03-22 2008-10-30 ノバルティス アクチエンゲゼルシャフト Biomarkers on the effectiveness of aliskiren as a hypertensive agent
WO2007056324A3 (en) * 2005-11-08 2007-11-29 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2007056324A2 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
US11096918B2 (en) 2005-11-09 2021-08-24 Novartis Pharmaceuticals Corporation Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations
US11642329B2 (en) 2005-11-09 2023-05-09 Novartis Pharmaceuticals Corporation Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations
KR101442272B1 (en) * 2006-06-23 2014-09-22 노파르티스 아게 Galenical formulations of aliskiren and hydrochlorothiazide
TWI457137B (en) * 2006-06-23 2014-10-21 Novartis Ag Galenical formulations of organic compounds
WO2007147596A1 (en) * 2006-06-23 2007-12-27 Novartis Ag Galenical formulations of aliskiren and hydrochlorothiazide
US8618172B2 (en) 2006-06-23 2013-12-31 Novartis Ag Galenical formulations of organic compounds
EP2311439A1 (en) * 2006-06-23 2011-04-20 Novartis AG Galenical formulations of aliskiren and hydrochlorothiazide
AU2007263261B2 (en) * 2006-06-23 2011-07-14 Novartis Ag Galenical formulations of aliskiren and hydrochlorothiazide
EP3391878A1 (en) * 2006-06-23 2018-10-24 Noden Pharma DAC Galenical formulations of organic compounds
WO2008023016A3 (en) * 2006-08-25 2009-01-29 Novartis Ag Galenic formulations of aliskiren
AU2007287549B2 (en) * 2006-08-25 2011-02-03 Novartis Ag Galenic formulations of aliskiren
WO2008023016A2 (en) * 2006-08-25 2008-02-28 Novartis Ag Galenic formulations of aliskiren
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
WO2008098992A1 (en) * 2007-02-16 2008-08-21 Novartis Ag Use of organic compounds
EA020331B1 (en) * 2007-03-23 2014-10-30 Крка, Товарна Здравил, Д.Д., Ново Место Process for manufacture of pharmaceutical formulation comprising aliskiren
WO2008116601A3 (en) * 2007-03-23 2009-07-23 Krka Tovarna Zdravil D D Novo Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
WO2008116601A2 (en) * 2007-03-23 2008-10-02 Krka, Tovarna Zdravil, D.D., Novo Mesto Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
US8236346B2 (en) 2007-10-05 2012-08-07 Alzheimer's Institute of America, Inc Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
US8236347B2 (en) 2007-10-05 2012-08-07 Alzheimer's Institute Of America, Inc. Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
US8613949B2 (en) 2008-09-22 2013-12-24 Novartis Ag Galenical formulations of organic compounds
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Also Published As

Publication number Publication date
NO334382B1 (en) 2014-02-24
CA2485081A1 (en) 2003-11-27
LU92000I2 (en) 2012-07-16
EP2316488A1 (en) 2011-05-04
JP2010280708A (en) 2010-12-16
PT1507558E (en) 2011-11-23
ES2369216T3 (en) 2011-11-28
EP1507558B8 (en) 2012-02-15
NO20045459L (en) 2004-12-15
CY2012011I1 (en) 2015-11-04
BR0310084A (en) 2005-02-15
CA2485081C (en) 2013-01-08
RU2316318C2 (en) 2008-02-10
JP2005526850A (en) 2005-09-08
PL219032B1 (en) 2015-03-31
KR20130109244A (en) 2013-10-07
ZA200408442B (en) 2006-02-22
CY1112013T1 (en) 2015-11-04
AU2003240669A1 (en) 2003-12-02
NZ536555A (en) 2007-03-30
IL164837A0 (en) 2005-12-18
RU2004137104A (en) 2005-09-10
EP1507558B1 (en) 2011-08-17
JP5288678B2 (en) 2013-09-11
SI1507558T1 (en) 2011-12-30
US20120071470A1 (en) 2012-03-22
MXPA04011383A (en) 2005-02-14
CN1655819A (en) 2005-08-17
HK1074774A1 (en) 2005-11-25
US8183295B2 (en) 2012-05-22
EP1507558A1 (en) 2005-02-23
IL164837A (en) 2013-12-31
DK1507558T3 (en) 2011-12-05
KR20100137026A (en) 2010-12-29
PL372203A1 (en) 2005-07-11
US20050182042A1 (en) 2005-08-18
ECSP045428A (en) 2005-01-03
CY2012011I2 (en) 2015-11-04
AU2003240669B2 (en) 2007-03-08
US20080300238A1 (en) 2008-12-04
ATE520417T1 (en) 2011-09-15
KR20050008717A (en) 2005-01-21

Similar Documents

Publication Publication Date Title
US8183295B2 (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
US8404744B2 (en) Methods of treatment and pharmaceutical composition
EP1467728B1 (en) Pharmaceutical compositions comprising valsartan and nep inhibitors
US20080119557A1 (en) Combination Of Organic Compounds
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
US20080261958A1 (en) Combination of Organic Compounds
WO2007045663A2 (en) Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
MX2007009663A (en) Combination of organic compounds
AU2006202999A1 (en) Pharmaceutical compositions comprising valsartan and NEP inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PH PL PT RO RU SC SE SG SK TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501787

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003730064

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/08442

Country of ref document: ZA

Ref document number: 200408442

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003240669

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2485081

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004505094

Country of ref document: JP

Ref document number: 536555

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/011383

Country of ref document: MX

Ref document number: 1020047018460

Country of ref document: KR

Ref document number: 1020047018479

Country of ref document: KR

Ref document number: 10514683

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1020047018460

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 372203

Country of ref document: PL

Ref document number: 2588/CHENP/2004

Country of ref document: IN

Ref document number: 2003811237X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2004137104

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1200401339

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020047018479

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003730064

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003240669

Country of ref document: AU